5 results on '"Kiec-Klimczak M"'
Search Results
2. Obesity and body fat classification in the metabolic syndrome: Impact on cardiometabolic risk metabotype
- Author
-
Phillips, C.M., Tierney, A.C., Perez Martinez, P., Defoort, C., Blaak, E.E., Gjelstad, I.M., Lopez Miranda, J., Kiec Klimczak, M., Malczewska-Malec, M., Drevon, C.A., Hall, W, Lovegrove, J.A., Karlstrom, B., Riserus, U., Roche, H.M., Humane Biologie, and RS: NUTRIM - R1 - Metabolic Syndrome
- Abstract
OBJECTIVE: Obesity is a key factor in the development of the metabolic (MetS), which is associated with increased cardiometabolic risk. We whether obesity classification by BMI and body fat percentage (BF%) cardiometabolic profile and dietary responsiveness in 486 MetS subjects dietary intervention study). DESIGN AND METHODS: Anthropometric of inflammation and glucose metabolism, lipid profiles, adhesion hemostatic factors were determined at baseline and after 12 weeks of interventions (high saturated fat (SFA), high monounsaturated fat low fat high complex carbohydrate (LFHCC) diets, one supplemented with n-3 polyunsaturated fatty acids (LC n-3 PUFAs)). RESULTS: About 39 and subjects classified as normal and overweight by BMI were obese according BF%. Individuals classified as obese by BMI (>/=30 kg/m(2) ) and BF% (men) and >/=35% (women)) (OO, n = 284) had larger waist and hip higher BMI and were heavier (P < 0.001) than those classified as but obese by BF% (NOO, n = 92). OO individuals displayed a more (higher C reactive protein (CRP) and leptin), prothrombotic (higher activator inhibitor-1 (PAI-1)), proatherogenic (higher and more insulin resistant (higher HOMA-IR) metabolic profile relative group (P < 0.001). Interestingly, tumor necrosis factor-alpha (TNF- concentrations were lower post-intervention in NOO individuals compared subjects (P < 0.001). CONCLUSIONS: In conclusion, assessing BF% and BMI of a metabotype may help to identify individuals at greater than BMI alone.
- Published
- 2013
3. Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes.
- Author
-
Razny U, Fedak D, Kiec-Wilk B, Goralska J, Gruca A, Zdzienicka A, Kiec-Klimczak M, Solnica B, Hubalewska-Dydejczyk A, and Malczewska-Malec M
- Subjects
- Adult, Aged, Biomarkers blood, Blood Glucose analysis, Energy Metabolism, Female, Follow-Up Studies, Humans, Inflammation blood, Male, Metabolic Diseases blood, Middle Aged, Obesity blood, Prediabetic State blood, Prognosis, Carboxylic Acids chemistry, Inflammation etiology, Insulin Resistance, Metabolic Diseases etiology, Obesity complications, Osteocalcin blood, Prediabetic State complications
- Abstract
Background: Carboxylated osteocalcin (Gla-OC) participates in bone remodeling, whereas the undercarboxylated form (Glu-OC) takes part in energy metabolism. This study was undertaken to compare the blood levels of Glu-OC and Gla-OC in nonobese, healthy obese, and prediabetic volunteers and correlate it with the metabolic markers of insulin resistance and early markers of inflammation., Methods: Nonobese (body mass index [BMI] <30 kg/m
2 ; n = 34) and obese subjects (302 ; n = 98), both sexes, aged 25 to 65 years, were divided into healthy control, normal weight subjects, healthy obese, and obese with biochemical markers of prediabetes. The subgroups with obesity and low or high Gla-OC or Glu-OC were also considered for statistical analysis. After 2 weeks of diet standardization, venous blood was sampled for the determination of Gla-OC, Glu-OC, lipid profile, parameters of inflammation (hsCRP, interleukin 6, sE-selectin, sPECAM-1, and monocyte chemoattractant protein 1), and adipokines (leptin, adiponectin, visfatin, and resistin)., Results: Gla-OC in obese patients was significantly lower compared to nonobese ones (11.36 ± 0.39 vs 12.69 ± 0.90 ng/mL, P = .048) and weakly correlated with hsCRP (r = -0.18, P = .042), visfatin concentration (r = -0.19, P = .033), and BMI (r = -0.17, P = .047). Glu-OC was negatively associated with fasting insulin levels (r = -0.18, P = .049) and reduced in prediabetic individuals compared with healthy obese volunteers (3.04 ± 0.28 vs 4.48 ± 0.57, P = .025)., Conclusions: Decreased blood concentration of Glu-OC may be a selective early symptom of insulin resistance in obesity, whereas the decreased level of Gla-OC seems to be associated with the appearance of early markers of low grade inflammation accompanying obesity., (© 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.) - Published
- 2017
- Full Text
- View/download PDF
4. Assessment of incretins in oral glucose and lipid tolerance tests may be indicative in the diagnosis of metabolic syndrome aggravation.
- Author
-
Kiec-Klimczak M, Malczewska-Malec M, Razny U, Zdzienicka A, Gruca A, Goralska J, Pach D, Gilis-Januszewska A, Dembinska-Kiec A, and Hubalewska-Dydejczyk A
- Subjects
- Adiponectin blood, Adult, Aged, Blood Glucose analysis, Cytokines blood, E-Selectin blood, Female, Glucagon-Like Peptide 1 blood, Glucose Tolerance Test, Humans, Insulin blood, Interleukin-6 blood, Leptin blood, Lipids blood, Male, Metabolic Syndrome diagnosis, Middle Aged, Nicotinamide Phosphoribosyltransferase blood, Fasting blood, Gastric Inhibitory Polypeptide blood, Metabolic Syndrome blood, Postprandial Period physiology
- Abstract
Incretins stimulated by oral meals are claimed to be protective for the pancreatic beta cells, to increase insulin secretion, to inhibit glucagon release, slow gastric emptying (glucagon-like peptide-1) and suppress appetite. Recently it has however been suggested that glucagon-like peptide-1 (GLP-1) is putative early biomarker of metabolic consequences of the obesity associated proinflammatory state. The study was aimed to compare the release of incretins and some of early markers of inflammation at the fasting and postprandial period induced by functional oral glucose as well as lipid load in healthy controls and patients with metabolic syndrome (MS) to see if functional tests may be helpful in searching for the inflammatory status of patients. Fifty patients with MS and 20 healthy volunteers (C) participated in this study. The 3-hour oral glucose (OGTT) and the 8-hour oral lipid (OLTT) tolerance tests were performed. At fasting leptin and adiponectin, as well as every 30 minutes of OGTT and every 2 hours of OLTT blood concentration of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), glucose, insulin, triglycerides, free fatty acids, glutathione peroxidase, interleukin-6, sE-selectin, monocyte chemoattractant protein-1 (MCP1) and visfatin were measured. At fasting and during both OGTT and OLTT the level of incretins did not differ between the MS and the C group. Both glucose and lipids reach food activated incretins secretion. Glucose was the main GLP-1 release activator, while the lipid load activated evidently GIP secretion. A significantly larger AUC-GIP after the lipid-rich meal over the carbohydrate meal was observed, while statistically bigger value of AUC-GLP-1 was noticed in OGTT than in OLTT (P < 0.001) within each of the investigated groups. In patients with the highest fasting plasma GIP concentration (3(rd) tertile), IL-6, MCP-1, sE-selectin and visfatin blood levels were increased and correlated with glutathione peroxydase, leptin/adiponectin ratio, higher visfatin and interleukin-6 levels. The fat containing meals stimulate the long-lasting release of incretins, mainly GIP, parallel to the increase of the markers of low grade inflammation associating obesity in metabolic syndrome. The possibility of use of the postprandial (OLTT) GIP release measurement for the low grade inflammation progress in MS patients is suggested.
- Published
- 2016
5. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype.
- Author
-
Phillips CM, Tierney AC, Perez-Martinez P, Defoort C, Blaak EE, Gjelstad IM, Lopez-Miranda J, Kiec-Klimczak M, Malczewska-Malec M, Drevon CA, Hall W, Lovegrove JA, Karlstrom B, Risérus U, and Roche HM
- Subjects
- Adiponectin blood, C-Reactive Protein metabolism, Diet Therapy, Female, Humans, Insulin Resistance, Leptin blood, Male, Middle Aged, Overweight, Plasminogen Activator Inhibitor 1 blood, Reference Values, Risk Factors, Tumor Necrosis Factor-alpha blood, Adipose Tissue, Body Composition, Body Mass Index, Cardiovascular Diseases blood, Cardiovascular Diseases etiology, Metabolic Syndrome blood, Metabolic Syndrome complications, Obesity blood, Obesity complications, Obesity diagnosis
- Abstract
Objective: Obesity is a key factor in the development of the metabolic syndrome (MetS), which is associated with increased cardiometabolic risk. We investigated whether obesity classification by BMI and body fat percentage (BF%) influences cardiometabolic profile and dietary responsiveness in 486 MetS subjects (LIPGENE dietary intervention study)., Design and Methods: Anthropometric measures, markers of inflammation and glucose metabolism, lipid profiles, adhesion molecules, and hemostatic factors were determined at baseline and after 12 weeks of four dietary interventions (high saturated fat (SFA), high monounsaturated fat (MUFA), and two low fat high complex carbohydrate (LFHCC) diets, one supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs))., Results: About 39 and 87% of subjects classified as normal and overweight by BMI were obese according to their BF%. Individuals classified as obese by BMI (≥ 30 kg/m(2)) and BF% (≥ 25% (men) and ≥ 35% (women)) (OO, n = 284) had larger waist and hip measurements, higher BMI and were heavier (P < 0.001) than those classified as nonobese by BMI but obese by BF% (NOO, n = 92). OO individuals displayed a more proinflammatory (higher C reactive protein (CRP) and leptin), prothrombotic (higher plasminogen activator inhibitor-1 (PAI-1)), proatherogenic (higher leptin/adiponectin ratio) and more insulin resistant (higher HOMA-IR) metabolic profile relative to the NOO group (P < 0.001). Interestingly, tumor necrosis factor-α (TNF-α) concentrations were lower post-intervention in NOO individuals compared with OO subjects (P < 0.001)., Conclusions: In conclusion, assessing BF% and BMI as part of a metabotype may help to identify individuals at greater cardiometabolic risk than BMI alone., (Copyright © 2012 The Obesity Society.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.